Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
Journal of Hepatocellular Carcinoma · 2026-10 · Volume 13 · 1-12
DOI: 10.2147/jhc.s638385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-10. Verfasst von Chien-Hung Lu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
- Division of Integrative Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- TMU Research Center for Digestive Medicine, Taipei Medical University, Taipei, Taiwan.
- Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan.
- Division of Hematology and Oncology, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan.
ORCID-Profile: Tsung-Hao Liu, San-Chi Chen
Zitieren
APA
Lu, C. H., Kao, W. Y., Hsieh, Y. Y., Wang, C. C., Wu, M. S., Wu, C. H., Liu, T. H., Ting, W. Y., Wu, S. C., Chuang, K. I., Su, C. W., Chang, C. C., & Chen, S. C. (2026). Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Journal of Hepatocellular Carcinoma, Volume 13, 1-12. https://doi.org/10.2147/jhc.s638385
Vancouver
Lu CH, Kao WY, Hsieh YY, Wang CC, Wu MS, Wu CH, et al. Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-12. doi:10.2147/jhc.s638385
BibTeX
@article{Lu2026,
author = {Lu, Chien-Hung and Kao, Wei-Yu and Hsieh, Yao-Yu and Wang, Chia-Chi and Wu, Ming-Shun and Wu, Chih-Horng and Liu, Tsung-Hao and Ting, Wei-Yi and Wu, Shan-Chia and Chuang, Kai-I and Su, Chien-Wei and Chang, Chun-Chao and Chen, San-Chi},
title = {Validation of the Up7-ALBI Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--12},
doi = {10.2147/jhc.s638385}
}
EUVIMED